>Amaechi UA, Sodipo BO, Nnaji CA, Owoyemi A, Omitiran K, Okedo-Alex IN,Eboreime E, Ajumobi O. Social approaches to COVID-19 pandemic response:effectiveness and practicality in sub-Saharan Africa. Pan Afr Med J. 2020 Sep2;37(Suppl 1):2. doi: 10.11604/pamj.supp.2020.37.2.25183. PMID: 33294103; PMCID:PMC7704349.

>Camposeragna A. Un altro effetto di CoViD-19: accendere le luci sullasituazione carceraria italiana [Another effect of CoViD-19: turning on thelights on the Italian prison situation.]. Recenti Prog Med. 2020May;111(5):287-289. Italian. doi: 10.1701/3366.33407. PMID: 32448876.

>Chan KY, Xu MS, Ching JC, So TM, Lai ST, Chu CM, Yam LY, Wong AT, Chung PH,Chan VS, Lin CL, Sham PC, Leung GM, Peiris JS, Khoo US. CD209 (DC-SIGN)-336A/G promoter polymorphism and severe acute respiratory syndrome in Hong Kong Chinese. Hum Immunol. 2010 Jul;71(7):702-7. doi: 10.1016/j.humimm.2010.03.006.Epub 2010 May 4. PMID: 20359516; PMCID: PMC7115401.

>Chen W, Wang Q, Li YQ, Yu HL, Xia YY, Zhang ML, Qin Y, Zhang T, Peng ZB,Zhang RC, Yang XK, Yin WW, An ZJ, Wu D, Yin ZD, Li S, Chen QL, Feng LZ, Li ZJ,Feng ZJ. [Early containment strategies and core measures for prevention andcontrol of novel coronavirus pneumonia in China]. Zhonghua Yu Fang Yi Xue ZaZhi. 2020 Mar 6;54(3):239-244. Chinese. doi:10.3760/cma.j.issn.0253-9624.2020.03.003. PMID: 32064856.

>Dong Y, Wang L, Burgner DP, Miller JE, Song Y, Ren X, Li Z, Xing Y, Ma J,Sawyer SM, Patton GC. Infectious diseases in children and adolescents in China:analysis of national surveillance data from 2008 to 2017. BMJ. 2020 Apr2;369:m1043. doi: 10.1136/bmj.m1043. PMID: 32241761; PMCID: PMC7114954.

>Giersing BK, Vekemans J, Nava S, Kaslow DC, Moorthy V; WHO ProductDevelopment for Vaccines Advisory Committee. Report from the World HealthOrganization's third Product Development for Vaccines Advisory Committee (PDVAC)meeting, Geneva, 8-10th June 2016. Vaccine. 2019 Nov 28;37(50):7315-7327. doi:10.1016/j.vaccine.2016.10.090. Epub 2017 Mar 3. PMID: 28262332; PMCID:PMC7131228.

>Hashemian SR, Aliannejad R, Zarrabi M, Soleimani M, Vosough M, Hosseini SE,Hossieni H, Keshel SH, Naderpour Z, Hajizadeh-Saffar E, Shajareh E, Jamaati H,Soufi-Zomorrod M, Khavandgar N, Alemi H, Karimi A, Pak N, Rouzbahani NH, NouriM, Sorouri M, Kashani L, Madani H, Aghdami N, Vasei M, Baharvand H. Mesenchymalstem cells derived from perinatal tissues for treatment of critically illCOVID-19-induced ARDS patients: a case series. Stem Cell Res Ther. 2021 Jan29;12(1):91. doi: 10.1186/s13287-021-02165-4. PMID: 33514427; PMCID: PMC7844804.

>Head MG, Brown RJ, Newell ML, Scott JAG, Batchelor J, Atun R. The allocation of USdollar;105 billion in global funding from G20 countries for infectious disease research between 2000 and 2017: a content analysis of investments. Lancet Glob Health. 2020 Oct;8(10):e1295-e1304. doi:10.1016/S2214-109X(20)30357-0. PMID: 32971052; PMCID: PMC7505652.

>Junqueira-Kipnis AP, Dos Anjos LRB, Barbosa LCS, da Costa AC, Borges KCM,Cardoso ADRO, Ribeiro KM, Rosa SBA, Souza CC, das Neves RC, Saraiva G, da SilvaSM, Silveira EA, Rabahi MF, Conte MB, Kipnis A. BCG revaccination of healthworkers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial.Trials. 2020 Oct 26;21(1):881. doi: 10.1186/s13063-020-04822-0. Erratum in:Trials. 2020 Nov 24;21(1):967. PMID: 33106170; PMCID: PMC7586662.

>Karmarkar E, Blanco I, Amornkul P, DuBois A, Deng X, Moonan PK, RubensteinBL, Miller DA, Kennedy I, Yu J, Dauterman J, Ongpin M, Hathaway W, Hoo L,Trammell S, Ememu E, Yu G, Khwaja Z, Lu W, Talai N, Jain S, Louie J, Philip S,Federman S, Masinde G, Wadford DA, Bobba N, Stoltey J, Smith A, Epson E, Chiu C,Bennett A, Vasquez AM, Williams T. Timely Intervention and Control of a NovelCoronavirus (COVID-19) Outbreak at a Large Skilled Nursing Facility - SanFrancisco, California, 2020. Infect Control Hosp Epidemiol. 2020 Dec 14:1-20.doi: 10.1017/ice.2020.1375. Epub ahead of print. PMID: 33308357.

>Khayat M, Fan H, Vali Y. COVID-19 promoting the development of active tuberculosis in a patient with latent tuberculosis infection: A case report.Respir Med Case Rep. 2021;32:101344. doi: 10.1016/j.rmcr.2021.101344. Epub 2021Jan 20. PMID: 33495728; PMCID: PMC7816563.

>Madsen AMR, Schaltz-Buchholzer F, Benfield T, Bjerregaard-Andersen M,Dalgaard LS, Dam C, Ditlev SB, Faizi G, Johansen IS, Kofoed PE, Kristensen GS,Loekkegaard ECL, Mogensen CB, Mohamed L, Ostenfeld A, Oedegaard ES, SoerensenMK, Wejse C, Jensen AKG, Nielsen S, Krause TG, Netea MG, Aaby P, Benn CS. UsingBCG vaccine to enhance non-specific protection of health care workers during theCOVID-19 pandemic: A structured summary of a study protocol for a randomisedcontrolled trial in Denmark. Trials. 2020 Sep 17;21(1):799. doi:10.1186/s13063-020-04714-3. PMID: 32943115; PMCID: PMC7495402.

>Magro P, Formenti B, Marchese V, Gulletta M, Tomasoni LR, Caligaris S,Castelli F, Matteelli A. Impact of the SARS-CoV-2 epidemic on tuberculosistreatment outcome in Northern Italy. Eur Respir J. 2020 Oct 1;56(4):2002665.doi: 10.1183/13993003.02665-2020. PMID: 32703780; PMCID: PMC7377210.

>Murhekar MV, Bhatnagar T, Selvaraju S, Rade K, Saravanakumar V, VivianThangaraj JW, Kumar MS, Shah N, Sabarinathan R, Turuk A, Anand PK, Asthana S,Balachandar R, Bangar SD, Bansal AK, Bhat J, Chakraborty D, Rangaraju C, ChopraV, Das D, Deb AK, Devi KR, Dwivedi GR, Salim Khan SM, Haq I, Kumar MS, LaxmaiahA, Madhuka, Mahapatra A, Mitra A, Nirmala AR, Pagdhune A, Qurieshi MA, RamaraoT, Sahay S, Sharma YK, Shrinivasa MB, Shukla VK, Singh PK, Viramgami A, WilsonVC, Yadav R, Girish Kumar CP, Luke HE, Ranganathan UD, Babu S, Sekar K, YadavPD, Sapkal GN, Das A, Das P, Dutta S, Hemalatha R, Kumar A, Narain K,Narasimhaiah S, Panda S, Pati S, Patil S, Sarkar K, Singh S, Kant R, Tripathy S,Toteja GS, Babu GR, Kant S, Muliyil JP, Pandey RM, Sarkar S, Singh SK, Zodpey S,Gangakhedkar RR, S Reddy DC, Bhargava B. Prevalence of SARS-CoV-2 infection inIndia: Findings from the national serosurvey, May-June 2020. Indian J Med Res.2020 Jul & Aug;152(1 & 2):48-60. doi: 10.4103/ijmr.IJMR_3290_20. PMID: 32952144;PMCID: PMC7853249.

>Murhekar MV, Bhatnagar T, Selvaraju S, Saravanakumar V, Thangaraj JWV, ShahN, Kumar MS, Rade K, Sabarinathan R, Asthana S, Balachandar R, Bangar SD, BansalAK, Bhat J, Chopra V, Das D, Deb AK, Devi KR, Dwivedi GR, Khan SMS, Kumar CPG,Kumar MS, Laxmaiah A, Madhukar M, Mahapatra A, Mohanty SS, Rangaraju C, Turuk A,Baradwaj DK, Chahal AS, Debnath F, Haq I, Kalliath A, Kanungo S, Kshatri JS,Lakshmi GGJN, Mitra A, Nirmala AR, Prasad GV, Qurieshi MA, Sahay S, Sangwan RK,Sekar K, Shukla VK, Singh PK, Singh P, Singh R, Varma DS, Viramgami A, Panda S,Reddy DCS, Bhargava B; ICMR Serosurveillance Group. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey. Lancet Glob Health. 2021 Jan 27;S2214-109X(20)30544-1. doi: 10.1016/S2214-109X(20)30544-1. PMID: 33515512.

>Odume B, Falokun V, Chukwuogo O, Ogbudebe C, Useni S, Nwokoye N, Aniwada E,Olusola Faleye B, Okekearu I, Nongo D, Odusote T, Lawanson A. Impact of COVID-19on TB active case finding in Nigeria. Public Health Action. 2020 Dec21;10(4):157-162. doi: 10.5588/pha.20.0037. PMID: 33437681; PMCID: PMC7790486.

>Smith CB, Battin MP, Jacobson JA, Francis LP, Botkin JR, Asplund EP, DomekGJ, Hawkins B. Are there characteristics of infectious diseases that raisespecial ethical issues? Dev World Bioeth. 2004 May;4(1):1-16. doi:10.1111/j.1471-8731.2004.00064.x. PMID: 15086371.

>Tian D, Yu Y, Wang Y, Zheng T. Comparison of trends in the quantity andvariety of Science Citation Index (SCI) literature on human pathogens betweenChina and the United States. Scientometrics. 2012;93(3):1019-1027. doi:10.1007/s11192-012-0772-z. Epub 2012 May 16. PMID: 32214557; PMCID: PMC7088817.

>Tola HH. Risk communication during novel corona-virus disease 2019 pandemicin low health service coverage setup: The case of Ethiopia. J Educ HealthPromot. 2020 Jun 30;9:143. doi: 10.4103/jehp.jehp_346_20. PMID: 32766328; PMCID:PMC7377153.

>Wiegand SB, Safaee Fakhr B, Carroll RW, Zapol WM, Kacmarek RM, Berra L.Rescue Treatment With High-Dose Gaseous Nitric Oxide in Spontaneously BreathingPatients With Severe Coronavirus Disease 2019. Crit Care Explor. 2020 Nov16;2(11):e0277. doi: 10.1097/CCE.0000000000000277. PMID: 33225304; PMCID:PMC7671879.

>Ye Q, Wang H, Xia X, Zhou C, Liu Z, Xia ZE, Zhang Z, Zhao Y, Yehenala J,Wang S, Zhou G, Hu K, Wu B, Wu CT, Wang S, He Y. Safety and efficacy assessmentof allogeneic human dental pulp stem cells to treat patients with COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II). Trials. 2020 Jun 12;21(1):520. doi: 10.1186/s13063-020-04380-5. PMID: 32532356; PMCID: PMC7290137.

